The global chromatin immunoprecipitation (ChIP) sequencing market accounted for USD 11.98 billion in 2023 and is expected to reach USD 37.13 billion by 2034 with a CAGR of 10.83% during the forecast period 2024-2034. Rising demand for advanced disease research, increased emphasis on personalized medicine, technological advancements, increased government funding, and research initiatives, increased emphasis on early disease detection, and increased need for biomarker discovery and validation will all contribute to market expansion.
Personalized medicine aims to tailor medical care to each patient's unique traits. ChIP sequencing identifies exact genetic and epigenetic modifications associated with diseases, allowing targeted therapies to be developed. As tailored medicine gains traction, demand for ChIP-sequencing services will rise. For instance, in December 2023, Thermo Fisher Scientific finalized the $450 million acquisition of Mesa Biotech, Inc., a molecular diagnostic test company.
By technology, the targeted sequencing and re-sequencing segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the increasing adoption of targeted therapies and precision medicine approaches across various disease areas, driving demand for accurate and high-throughput sequencing techniques like ChIP-sequencing. For instance, in December 2023, Active Motif announced the release of its ChIP-IT Express Chromatin Immunoprecipitation Kit, which is intended to simplify and accelerate chromatin immunoprecipitation operations. Additionally, the whole exome sequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the potential of whole exome sequencing in identifying rare genetic variants associated with diseases, facilitating personalized medicine, and targeted treatment approaches.
By workflow, the pre-sequencing segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the increased demand for sample preparation and quality control solutions before sequencing, ensuring accurate and reliable results in ChIP-sequencing experiments. For instance, Zymo Research announced the release of their ChIP DNA Clean & ConcentratorTM Kits in January 2023. These kits offer a simplified method for purifying and concentrating DNA after chromatin immunoprecipitation. Additionally, the data analysis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising complexity of genomic data generated from ChIP-sequencing experiments, driving demand for advanced bioinformatics tools and software for efficient data analysis and interpretation.
By end-user, the academic research institutes segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the growing investment in basic research and epigenetic studies by academic institutions, leveraging ChIP sequencing for advancing scientific knowledge and understanding disease mechanisms. For instance, in November 2023, Illumina announced the acquisition of GRAIL, a healthcare business focused on multi-cancer early detection, for almost $8 billion. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on drug discovery and development, utilizing ChIP sequencing for target identification, validation, and personalized medicine initiatives.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust infrastructure for biomedical research, the strong presence of key market players, and the supportive regulatory environment promoting the adoption of advanced sequencing technologies like ChIP-sequencing. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing research activities, rising healthcare expenditure, and raising awareness about personalized medicine and genomics applications, driving the adoption of ChIP-sequencing technologies in the region. For instance, Takara Bio debuted its SMART ChIP-Seq Kit in November 2023, providing a simplified approach to high-throughput sequencing library preparation and chromatin immunoprecipitation.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Personalized medicine aims to tailor medical care to each patient's unique traits. ChIP sequencing identifies exact genetic and epigenetic modifications associated with diseases, allowing targeted therapies to be developed. As tailored medicine gains traction, demand for ChIP-sequencing services will rise. For instance, in December 2023, Thermo Fisher Scientific finalized the $450 million acquisition of Mesa Biotech, Inc., a molecular diagnostic test company.
By technology, the targeted sequencing and re-sequencing segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the increasing adoption of targeted therapies and precision medicine approaches across various disease areas, driving demand for accurate and high-throughput sequencing techniques like ChIP-sequencing. For instance, in December 2023, Active Motif announced the release of its ChIP-IT Express Chromatin Immunoprecipitation Kit, which is intended to simplify and accelerate chromatin immunoprecipitation operations. Additionally, the whole exome sequencing segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of the potential of whole exome sequencing in identifying rare genetic variants associated with diseases, facilitating personalized medicine, and targeted treatment approaches.
By workflow, the pre-sequencing segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the increased demand for sample preparation and quality control solutions before sequencing, ensuring accurate and reliable results in ChIP-sequencing experiments. For instance, Zymo Research announced the release of their ChIP DNA Clean & ConcentratorTM Kits in January 2023. These kits offer a simplified method for purifying and concentrating DNA after chromatin immunoprecipitation. Additionally, the data analysis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising complexity of genomic data generated from ChIP-sequencing experiments, driving demand for advanced bioinformatics tools and software for efficient data analysis and interpretation.
By end-user, the academic research institutes segment accounted for the highest revenue-grossing segment in the global chromatin immunoprecipitation (ChIP) sequencing market in 2023 owing to the growing investment in basic research and epigenetic studies by academic institutions, leveraging ChIP sequencing for advancing scientific knowledge and understanding disease mechanisms. For instance, in November 2023, Illumina announced the acquisition of GRAIL, a healthcare business focused on multi-cancer early detection, for almost $8 billion. Additionally, the pharmaceutical and biotechnology company segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing focus on drug discovery and development, utilizing ChIP sequencing for target identification, validation, and personalized medicine initiatives.
North American region is anticipated to have the highest revenue share during the forecast period owing to the robust infrastructure for biomedical research, the strong presence of key market players, and the supportive regulatory environment promoting the adoption of advanced sequencing technologies like ChIP-sequencing. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the increasing research activities, rising healthcare expenditure, and raising awareness about personalized medicine and genomics applications, driving the adoption of ChIP-sequencing technologies in the region. For instance, Takara Bio debuted its SMART ChIP-Seq Kit in November 2023, providing a simplified approach to high-throughput sequencing library preparation and chromatin immunoprecipitation.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Technology, Workflow, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Chromatin Immunoprecipitation (ChIP) Sequencing Market Report 2023 - 2034
Chromatin Immunoprecipitation (ChIP) Sequencing Market Analysis & Forecast by Technology 2023 - 2034 (Revenue USD Bn)
- Targeted Sequencing and Re-Sequencing
- Whole Genome Sequencing
- Whole Exome Sequencing
Chromatin Immunoprecipitation (ChIP) Sequencing Market Analysis & Forecast by Workflow 2023 - 2034 (Revenue USD Bn)
- Pre-Sequencing
- Sequencing
- Data analysis
Chromatin Immunoprecipitation (ChIP) Sequencing Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Academic Research Institutes
- Clinical Research Institutes
- Hospitals and Clinics
- Pharmaceuticals and Biotechnology Companies
- Others
Chromatin Immunoprecipitation (ChIP) Sequencing Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Chromatin Immunoprecipitation (ChIP) Sequencing Market: Technology Estimates & Trend Analysis
8. Chromatin Immunoprecipitation (ChIP) Sequencing Market: Workflow Estimates & Trend Analysis
9. Chromatin Immunoprecipitation (ChIP) Sequencing Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Chromatin Immunoprecipitation (ChIP) Sequencing Market
12. Europe Global Chromatin Immunoprecipitation (ChIP) Sequencing Market
13. Asia Pacific Global Chromatin Immunoprecipitation (ChIP) Sequencing Market
14. Latin America Global Chromatin Immunoprecipitation (ChIP) Sequencing Market
15. MEA Global Chromatin Immunoprecipitation (ChIP) Sequencing Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc.
- Qiagen N.V.
- Merck KGaA (EMD Millipore)
- Bio-Rad Laboratories Inc.
- PerkinElmer Inc.
- Abcam plc
- Active Motif
- Zymo Research Corporation
- Diagenode Inc.
- Takara Bio Inc.
- Becton
- Dickinson and Company (BD)
- GenScript Biotech Corporation
- Chromatrap.
